Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on June 24, 2026. The filing reports a corporate governance event under Item 8.01 (Other Events) regarding the appointment of a new executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Alex Hastie, Ph.D. as the Company's Chief Scientific Officer. This appointment is effective as of July 20, 2026.
Guidance, Outlook, and Management Commentary
The filing incorporates a press release (Exhibit 99.1) announcing the appointment but does not include specific financial guidance, forward-looking outlooks, risk factors, or contingencies within the body of this text. The report was signed by Albert A. Luderer, Ph.D., Interim Chief Executive Officer.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on Dr. Hastie's background and strategic rationale.
- Confirm the effective start date of July 20, 2026, for the new Chief Scientific Officer.
- Review recent 10-Q or 10-K filings for the most current financial performance data, as this 8-K contains none.